Wells Fargo assumed coverage of Alaunos Therapeutics with an Overweight rating and $3 price target, with no changes made to rating or target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TCRT: